Chinese Drug Regulators Extend Rare Fast-track Approval For J&J Drug
This article was originally published in PharmAsia News
Executive SummaryHONG KONG - In an extremely rare case of fast-track approval for a special class of medicines, Chinese drug regulators have given the green light for a Johnson & Johnson drug to be launched nationwide before the completion of clinical trials inside China
You may also be interested in...
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).